WBC
NBIX icon

Westpac Banking Corp’s Neurocrine Biosciences NBIX Stock Holding History

Westpac Banking Corp’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,615
Closed -$213K – 524
2026
Q1 		$213K Buy
1,615
+91
+6% +$12.1K 0.01% 360
2025
Q4 		$216K Sell
1,524
-6
-0.4% -$869 0.01% 346
2025
Q3 		$215K Sell
1,530
-2,698
-64% -$366K 0.01% 334
2025
Q2 		$531K Sell
4,228
-56
-1% -$6.42K 0.04% 256
2025
Q1 		$474K Sell
4,284
-9,705
-69% -$1.23M 0.03% 261
2024
Q4 		$1.91M Buy
13,989
+1,429
+11% +$177K 0.13% 163
2024
Q3 		$1.45M Buy
12,560
+6,170
+97% +$846K 0.1% 194
2024
Q2 		$880K Sell
6,390
-396
-6% -$54.3K 0.07% 209
2024
Q1 		$936K Hold
6,786
– – 0.07% 210
2023
Q4 		$894K Buy
6,786
+4,805
+243% +$553K 0.07% 204
2023
Q3 		$223K Sell
1,981
-287
-13% -$30.2K 0.02% 369
2023
Q2 		$214K Sell
2,268
-4,828
-68% -$472K 0.02% 362
2023
Q1 		$718K Hold
7,096
– – 0.01% 702
2022
Q4 		$848K Hold
7,096
– – 0.01% 640
2022
Q3 		$754K Hold
7,096
– – 0.01% 667
2022
Q2 		$692K Hold
7,096
– – 0.01% 718
2022
Q1 		$665K Hold
7,096
– – 0.01% 748
2021
Q4 		$604K Hold
7,096
– – 0.01% 768
2021
Q3 		$681K Hold
7,096
– – 0.01% 772
2021
Q2 		$691K Hold
7,096
– – 0.01% 795
2021
Q1 		$690K Hold
7,096
– – 0.01% 745
2020
Q4 		$680K Hold
7,096
– – 0.01% 788
2020
Q3 		$682K Hold
7,096
– – 0.01% 747
2020
Q2 		$866K Hold
7,096
– – 0.01% 673
2020
Q1 		$614K Hold
7,096
– – 0.01% 691
2019
Q4 		$763K Buy
+7,096
New +$743K 0.01% 741

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Westpac Banking Corp's NBIX Position: Q2 2026 in Review

Westpac Banking Corp sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 1,615 shares — an estimated $213K sold.

Westpac Banking Corp first reported a position in NBIX in Q4 2019 and held it in 26 quarters. The position peaked at $1.91M in Q4 2024. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Westpac Banking Corp reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Westpac Banking Corp sold 1,615 Neurocrine Biosciences shares in Q2 2026, an estimated $213K.
  • Westpac Banking Corp first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 26 quarters.
  • Westpac Banking Corp's Neurocrine Biosciences position peaked at $1.91M in Q4 2024.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Westpac Banking Corp's 13F filing for Q2 2026, filed 12 Aug 2026.